Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the US and Canada
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jan 24
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally
18 Jan 24
Along with istaroxime, the agreement licences Windtree’s preclinical next-generation SERCA2a activators, called dual mechanism SERCA2a activators
11 Jan 24
WuXi Biologics will grant exclusive rights to the investigational monoclonal antibodies to BioNTech in exchange for an upfront…
08 Jan 24
The products covered by the agreement are Ascendis Pharma's Skytrofa (lonapegsomatropin), a weekly injectable paediatric human growth hormone…
05 Jan 24
The latest partnership, which is the second research strategic collaboration between Boehringer Ingelheim and 3T, will leverage Boehringer…
05 Jan 24
The partnership capitalises on MOMA's KnowledgeBase platform to pinpoint and advance novel precision oncology targets characterised by high…
05 Jan 24
The partnership intends to combine Umoja's proprietary VivoVec gene delivery platform with AbbVie's expertise in oncology to develop…
04 Jan 24
The collaboration will combine Ribo’s experience in discovering and developing small interfering RNA (siRNA) therapeutics with Boehringer’s capabilities…
04 Jan 24
Under the agreement, Remix will handle the discovery and preclinical phases, while Roche will assume responsibility for the…
03 Jan 24
Roche will obtain exclusive global rights to develop, manufacture, and commercialise MediLink’s cancer drug candidate YL211, in exchange…